Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in native American communities

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 280-288

  Scott, Jennifer R ^a   Millar, Eugene V ^b   Lipsitch, Marc ^c   Moulton, Lawrence H ^a   Weatherholtz, Robert ^a   Perilla, Mindy J ^a   Jackson, Delois M ^d   Beall, Bernard ^d   Craig, Mariddie J ^e   Reid, Raymond ^a   Santosham, Mathuram ^a   O'Brien, Katherine L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e White Mountain Apache Tribe   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AMERICAN INDIAN; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM CARRIER; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HOUSEHOLD; HUMAN; INFECTION SENSITIVITY; LONGITUDINAL STUDY; MALE; MORBIDITY; NASOPHARYNX; OBSERVATIONAL STUDY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SCHOOL CHILD; SEROTYPE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARRIER STATE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; FEMALE; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; NASOPHARYNX; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PREVALENCE; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; YOUNG ADULT;

EID: 84555188726     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir730     Document Type: Article

References (28)

1. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46. (Pubitemid 36514704)
2. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
3. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009; 124:e1-11.
4. Park SY, Moore MR, Bruden DL, et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J 2008; 27:335-40. (Pubitemid 351483069)
5. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008; 47:989-96.
6. Millar EV, O'Brien KL, Watt JP, et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006; 43:8-15. (Pubitemid 43939070)
7. Millar EV, O'Brien KL, Scott JR, et al. Near elimination of vaccine-type pneumococcal carriage by pneumococcal conjugate vaccine in a community at high risk of carriage and disease. In: Abstracts of the 6th International Symposium on Pneumococci and Pneumococcal Diseases (Reykjavik, Iceland). Congress Reykjavik, 2008.
8. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54. (Pubitemid 351412007)
9. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443-9. (Pubitemid 38280781)
10. Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 2007; 26:461-7. (Pubitemid 46847303)
11. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004; 190:1203-11. (Pubitemid 39287745)
12. Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 2010; 50:1238-46.
13. Millar EV, O'Brien KL, Zell ER, Bronsdon MA, Reid R, Santosham M. Nasopharyngeal carriage of Streptococcus pneumoniae in Navajo and White Mountain Apache children before the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2009; 28:711-16.
14. Millar EV, Pimenta FC, Roundtree A, et al. Pre-and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis 2010; 51:1258-65.
15. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007; 45:1225-33. (Pubitemid 46626489)
16. Mercado E, Srinivasan V, Hawkins P, et al. First report of Streptococcus pneumoniae serotype 6D in South America. J Clin Microbiol 2011; 49:2080-1.
17. Melnick N, Thompson TA, Beall BW. Serotype-specific typing antisera for pneumococcal serogroup 6 serotypes 6A, 6B, and 6C. J ClinMicrobiol 2010; 48:2311-2.
18. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. New York: Chapman and Hall, 1989.
19. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of sevenvalent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362:355-61. (Pubitemid 36945058)
20. Indian Health Service. Indian Health Service user population statistics. Indian Health Service, Department of Health and Human Services 2008.
21. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326:219. (Pubitemid 36143396)
22. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-35.
23. O'Brien KL, Shaw J, Weatherholtz R, et al. Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. Am J Epidemiol 2004; 160:270-8. (Pubitemid 39006783)
24. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 1999; 103:E28.
25. da Gloria Carvalho M, Pimenta FC, Jackson D, et al. Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. J Clin Microbiol 2010; 48:1611-8.
26. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007; 196:1211-20. (Pubitemid 47580276)
27. Lipsitch M. Bacterial vaccines and serotype replacement: Lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999; 5:336-45. (Pubitemid 29289447)
28. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. 13-valent pneumococcal conjugate vaccine elicits strong opsonophagocytic killing (OPA) activity to Streptococcus pneumoniae serotypes 6A, 6B, and 6C. In: Abstracts of the 7th International Symposium on Pneumococci and Pneumococcal Diseases (Tel Aviv, Israel). Kenes International, 2010.